Demcizumab
- Generic Name
- Demcizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1243262-17-0
- Unique Ingredient Identifier
- SF168W7FW0
- Background
Demcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung.
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- OncoMed Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT02722954
- Locations
- 🇬🇧
The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
🇺🇸The START Center for Cancer Care, San Antonio, Texas, United States
🇺🇸Rocky Mountain Cancer Center, Denver, Colorado, United States
Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2020-09-28
- Lead Sponsor
- OncoMed Pharmaceuticals, Inc.
- Target Recruit Count
- 207
- Registration Number
- NCT02289898
- Locations
- 🇺🇸
Lynn Cancer Institute, Boca Raton, Florida, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States
🇦🇺St John of God Murdoch Hospital, Murdoch, Western Australia, Australia
A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-10-08
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- OncoMed Pharmaceuticals, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT02259582
- Locations
- 🇧🇪
Centre Hospitalier Jolimont-Lobbes, La Louviere, Belgium
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian
- First Posted Date
- 2013-09-27
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- OncoMed Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01952249
- Locations
- 🇺🇸
University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸The University of Texas MD Anderson Cancer Center Department of Gynecologic Oncology, Houston, Texas, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2010-08-27
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- OncoMed Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT01189968
- Locations
- 🇪🇸
START Madrid, Madrid, Spain
🇦🇺Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
🇦🇺Monash Medical Centre, Clayton, Victoria, Australia
A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-08-27
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- OncoMed Pharmaceuticals, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT01189929
- Locations
- 🇪🇸
START Madrid, Madrid, Spain
🇦🇺Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇳🇿Christchurch Hospital, Christchurch, New Zealand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.